ERGIC2 Antibody

What is ERGIC2 and why is it important in cellular research?

ERGIC2 (Endoplasmic reticulum-Golgi intermediate compartment protein 2) is a protein with a potential role in transport between the endoplasmic reticulum and Golgi apparatus . Research has revealed ERGIC2's involvement in membrane contacts between the ER-Golgi intermediate compartment (ERGIC) and ER-exit sites (ERES), suggesting its importance in intracellular trafficking mechanisms . Additionally, ERGIC2 has been identified as an interacting partner of Otoferlin, particularly in brain tissue, pointing to tissue-specific functions . Understanding ERGIC2 is crucial for researchers studying intracellular vesicle trafficking, autophagosome formation, and organelle communication within the secretory pathway.

What applications are ERGIC2 antibodies most commonly used for?

ERGIC2 antibodies are utilized across multiple experimental applications, with Western blotting (WB), immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), and immunofluorescence (IF) being the most prevalent . When selecting an ERGIC2 antibody, researchers should prioritize those validated for their specific application. For instance, antibody ABIN2775870 has been validated for Western blotting using cell lysate as a positive control , while other antibodies such as ABIN7151695 have demonstrated efficacy across multiple applications including ELISA and immunofluorescence . The methodological approach should involve reviewing validation data and citations when available to ensure antibody reliability for your specific experimental context.

What species reactivity should I consider when selecting an ERGIC2 antibody?

Species reactivity is a critical consideration when selecting an ERGIC2 antibody. Commercial antibodies show variable cross-reactivity profiles. For example, ABIN2775870 reacts with human, mouse, rat, dog, guinea pig, rabbit, cow, horse, and zebrafish (Danio rerio) samples, with predicted reactivity percentages ranging from 79% in zebrafish to 100% in several mammals . Another antibody, ab237761, has been validated for human, mouse, and rat samples . When planning experiments involving less common research models, examine the antibody's predicted reactivity based on sequence homology. For cross-species studies, select antibodies targeting highly conserved epitopes, ideally with validation data across your species of interest.

How does the selection of antibody binding regions impact ERGIC2 detection?

The selection of binding regions significantly affects ERGIC2 detection outcomes. Commercial ERGIC2 antibodies target various regions including the N-terminus, middle region, C-terminus, or specific amino acid sequences . For instance, ABIN2775870 targets the middle region of ERGIC2 , while ABIN7151695 targets amino acids 55-310 . The binding region choice should align with your research objectives:

Consider protein structure, potential post-translational modifications, and known functional domains when selecting antibodies targeting specific regions.

How should Western blot protocols be optimized for ERGIC2 detection?

Optimizing Western blot protocols for ERGIC2 detection requires careful consideration of several parameters:

• Sample preparation: For cellular samples, use NP40 or similar non-denaturing detergents in lysis buffers to preserve ERGIC2's native structure. Include protease inhibitors to prevent degradation.

• Antibody dilution: Start with manufacturer recommendations and optimize as needed. For instance, ABIN2775870 is recommended at 1:500-1:2000 dilution for Western blotting .

• Blocking conditions: Use 5% non-fat dry milk or BSA in TBST for blocking. Test both if experiencing background issues.

• Controls: Include positive controls such as HeLa cell lysates or brain tissue lysates, which have been validated for ERGIC2 expression . The expected molecular weight for ERGIC2 is approximately 43 kDa .

• Detection method: For low abundance samples, consider enhanced chemiluminescence or fluorescent secondary antibodies for improved sensitivity.

• Stripping and reprobing: If analyzing multiple proteins from the same membrane, use mild stripping conditions to preserve ERGIC2 epitopes.

Validation should include detection of the predicted 43 kDa band across multiple cell or tissue types known to express ERGIC2, such as brain tissue lysates from mouse or rat .

What controls are essential when using ERGIC2 antibodies for immunohistochemistry?

When conducting immunohistochemistry with ERGIC2 antibodies, implement these essential controls:

• Positive tissue controls: Include tissues with known ERGIC2 expression, such as pancreatic tissue or brain sections . Both rodent and human samples have been validated for ERGIC2 detection.

• Negative controls:

  • Primary antibody omission: Incubate sections with antibody diluent only

  • Isotype controls: Use non-specific IgG from the same host species (e.g., rabbit IgG for rabbit polyclonal antibodies)

  • Absorption controls: Pre-incubate primary antibody with recombinant ERGIC2 protein

• Titration series: Test multiple antibody concentrations (typically 1:50-1:200 for IHC ) to determine optimal signal-to-noise ratio.

• Cross-reactivity assessment: If studying tissues with known expression of ERGIC2 family members, validate specificity using knockout/knockdown samples when possible.

• Antigen retrieval optimization: For ERGIC2 detection in paraffin-embedded tissues, high-pressure citrate buffer (pH 6.0) has been effective for epitope unmasking .

Documenting these controls is crucial for publication and reproducibility purposes.

How can I validate the specificity of my ERGIC2 antibody?

Validating ERGIC2 antibody specificity requires a multi-faceted approach:

• Knockout/knockdown validation: The gold standard approach involves comparing staining patterns between wild-type samples and those with ERGIC2 gene knockout or knockdown.

• Recombinant protein controls: Use purified recombinant ERGIC2 in Western blot assays to confirm antibody binding to the target protein.

• Peptide competition assays: Pre-incubate antibody with the immunizing peptide before application to samples; specific staining should be blocked.

• Multiple antibodies approach: Compare staining patterns using antibodies targeting different epitopes of ERGIC2; consistent patterns suggest specificity.

• Mass spectrometry validation: For immunoprecipitation applications, verify pulled-down proteins by mass spectrometry, as described in ERGIC isolation protocols .

• Cross-species validation: If the antibody claims cross-reactivity, verify consistent staining patterns across species with high sequence homology.

This comprehensive validation is particularly important given documented issues with antibody specificity in the field, such as cases where widely used antibodies were found to be non-specific for their targets, potentially invalidating clinical trial results .

What are recommended parameters for ERGIC2 co-localization studies using immunofluorescence?

For effective ERGIC2 co-localization studies using immunofluorescence:

• Fixation optimization:

  • For membrane structures: 4% paraformaldehyde (10-15 minutes)

  • For preserving membrane contacts: 0.1-0.2% glutaraldehyde with paraformaldehyde

• Permeabilization conditions:

  • Gentle permeabilization with 0.1-0.2% Triton X-100 or 0.05% saponin to preserve ERGIC-ERES membrane contacts

• Antibody selection and validation:

  • Use antibodies validated specifically for IF applications, such as ABIN7151695

  • Validate antibody specificity in single-staining experiments before co-localization studies

• Co-staining markers:

  • ERGIC-53: Standard marker for ERGIC compartment

  • SEC12: For ERES visualization (shown to interact with ERGIC2)

  • Otoferlin: For studying ERGIC2 interactions in neuronal tissues

• Imaging parameters:

  • High-resolution confocal microscopy with appropriate channel separation

  • For ERGIC-ERES contacts, super-resolution microscopy is recommended due to the close proximity (2-5 nm) of these structures

• Quantitative analysis:

  • Use Pearson's correlation coefficient or Manders' overlap coefficient for quantifying co-localization

  • Analyze multiple cells (>30) across different experiments for statistical robustness

For studies of ERGIC-ERES membrane contacts, note that these contacts are characterized by distances as short as 2-5 nm, requiring high-resolution imaging techniques for accurate visualization .

How can ERGIC2 antibodies be utilized to study autophagosome formation?

ERGIC2 antibodies provide valuable tools for investigating the role of ERGIC in autophagosome formation:

• Membrane contact visualization: ERGIC2 antibodies can help visualize ERGIC-ERES contacts that orchestrate autophagosome generation during cellular stress . This application requires:

  • High-resolution confocal or super-resolution microscopy

  • Co-staining with autophagosome markers like LC3

  • Time-course experiments following autophagy induction

• Immunoisolation of ERGIC membranes: A method combining ERGIC2 antibodies with LC3 immunoprecipitation can be implemented:

  • Use cell-free lipidation assays with ERGIC membranes

  • Employ FLAG-tagged LC3 for immunoisolation of lipidated ERGIC

  • Analyze isolated membranes by Western blot and mass spectrometry

• ERGIC-COPII vesicle characterization: ERGIC2 antibodies can track the formation of ERGIC-derived COPII vesicles that serve as membrane sources for autophagosomes:

  • Perform sequential immunolabeling of ERGIC2 and COPII components

  • Use immuno-electron microscopy to visualize budding COPII vesicles from ERGIC membranes

  • Employ live-cell imaging with fluorescently tagged ERGIC2 antibody fragments

• Stress-induced ERGIC remodeling: Monitor ERGIC morphological changes during autophagy induction:

  • Compare ERGIC2 distribution patterns before and after starvation

  • Quantify changes in ERGIC size, number, and proximity to autophagosome formation sites

These approaches have revealed that the ERGIC acts as a membrane platform that orchestrates autophagosome generation through contact formation with ERES during cellular stress .

What methodologies can reveal ERGIC2's protein-protein interactions?

Multiple complementary methodologies can uncover ERGIC2's protein-protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Protocol: Lyse cells in IP buffer (50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% NP40, 10% glycerol) with protease inhibitors

  • Incubate cleared lysates with ERGIC2 antibody-conjugated agarose beads

  • Wash extensively and analyze precipitated complexes by immunoblotting

  • Example: This approach successfully detected ERGIC2-Otoferlin interaction in brain tissue

• Yeast two-hybrid screening:

  • Used successfully to identify ERGIC2 as an Otoferlin binding partner using baits covering parts of Otoferlin's C2D domain

  • Confirm interactions with secondary validation methods

• Peptide pull-down assays:

  • Conjugate synthetic peptides (250 μg) to agarose beads

  • Incubate with purified proteins (e.g., 2 μg FLAG-tagged proteins)

  • Wash and analyze by immunoblotting

• Proximity labeling:

  • Express ERGIC2 fused to enzymes like BioID or APEX2

  • Identify proximal proteins through biotinylation and mass spectrometry

• Fluorescence resonance energy transfer (FRET):

  • Tag ERGIC2 and potential binding partners with appropriate fluorophore pairs

  • Measure energy transfer to identify close associations in live cells

An important consideration is that protein interactions may be tissue-specific, as demonstrated by the ERGIC2-Otoferlin interaction detected in brain but not in cochlea despite both proteins being expressed in both tissues .

How do ERGIC2 antibodies help characterize the ERGIC-ERES membrane contact?

ERGIC2 antibodies provide critical tools for characterizing the novel ERGIC-ERES membrane contact:

• Ultrastructural analysis:

  • Immuno-electron microscopy using ERGIC2 antibodies can visualize the unusually close (2-5 nm) membrane contact between ERGIC and ERES

  • This proximity is significantly closer than conventional organelle contacts (10-30 nm), enabling unique functions like transactivation

• Contact site dynamics:

  • Track formation and dissolution of contacts using live-cell imaging with fluorescently labeled ERGIC2 antibody fragments

  • Correlate contact dynamics with cellular stress responses and autophagosome formation

• Functional studies of transactivation:

  • Investigate how ERES-localized SEC12 reaches ERGIC membrane at contact sites

  • Use ERGIC2 antibodies in combination with the RUSH system to study SEC12 translocation

  • Monitor COPII vesicle formation at contact sites using triple-labeling approaches

• Quantitative contact site analysis:

  • Measure contact site dimensions in different cell types and conditions

  • Correlate contact site abundance with cellular functions like autophagy and secretion

• Protein complex characterization at contact sites:

  • Use ERGIC2 antibodies for proximity labeling at contact sites to identify additional components

  • Perform sequential immunoprecipitation to isolate specific subcomplexes

These methodologies have revealed that ERGIC-ERES contacts allow for both transactivation (where SEC12 reaches across to trigger COPII formation on ERGIC) and protein translocation (where SEC12 relocates from ERES to ERGIC) to coordinate autophagosome precursor formation .

What techniques differentiate ERGIC2's functions across tissue types?

To differentiate ERGIC2's tissue-specific functions, researchers can employ these methodological approaches:

• Comparative tissue expression profiling:

  • Use qRT-PCR to quantify ERGIC2 mRNA levels across tissues

  • Perform Western blot analysis with ERGIC2 antibodies to compare protein expression

  • This approach revealed ERGIC2 expression in both cochlea and brain before and after hearing onset

• Tissue-specific interactome analysis:

  • Conduct parallel co-immunoprecipitation experiments across tissues

  • Compare binding partners identified by mass spectrometry

  • This methodology demonstrated that ERGIC2 co-precipitated with Otoferlin in brain but not in cochlea, despite both proteins being present in both tissues

• Immunohistochemical co-localization studies:

  • Compare ERGIC2 distribution patterns across tissues using antibodies like ab237761

  • Co-stain with tissue-specific markers and potential interacting partners

  • This approach showed overlap between ERGIC2 and Otoferlin signals in inner hair cells and neurons of cerebral cortical layer I

• Conditional knockout models:

  • Generate tissue-specific ERGIC2 knockout animals

  • Compare phenotypic consequences across tissues

• Subcellular fractionation analysis:

  • Isolate organelle fractions from different tissues

  • Compare ERGIC2 distribution using immunoblotting

These approaches collectively suggest that ERGIC2 forms tissue-specific protein complexes with different functional roles across tissues , highlighting the importance of studying this protein in multiple physiological contexts.

Why might Western blots show different ERGIC2 molecular weights?

Variations in ERGIC2 molecular weight on Western blots can result from several biological and technical factors:

• Post-translational modifications (PTMs):

  • Phosphorylation can add approximately 80 Da per site

  • Glycosylation can substantially increase apparent molecular weight

  • Ubiquitination adds approximately 8.5 kDa per ubiquitin moiety

• Sample preparation variations:

  • Incomplete denaturation can cause anomalous migration

  • Different lysis buffers may preserve or disrupt certain protein modifications

  • Heat treatment duration can affect migration patterns

• Protein isoforms:

  • Alternative splicing may generate variant ERGIC2 forms with different molecular weights

  • Tissue-specific isoforms might be present in different samples

• Technical considerations:

  • Gel percentage affects relative migration distances

  • Running buffer composition can influence migration patterns

  • Molecular weight standards from different manufacturers may show slight variations

• Protein degradation:

  • Partial proteolytic degradation might generate lower molecular weight bands

  • Add protease inhibitors to all sample preparation buffers

While the predicted molecular weight of ERGIC2 is 43 kDa , variations between 40-45 kDa might be observed. Document exact sample preparation methods, gel conditions, and antibody used when reporting ERGIC2 molecular weights in publications.

How can I troubleshoot weak or inconsistent ERGIC2 signals in immunofluorescence?

To address weak or inconsistent ERGIC2 immunofluorescence signals:

• Fixation optimization:

  • Test multiple fixation methods (4% PFA, methanol, or combination)

  • Adjust fixation duration (10-20 minutes)

  • Consider light fixation for better epitope preservation

• Antibody selection and optimization:

  • Use antibodies specifically validated for IF, such as ABIN7151695

  • Optimize concentration through a titration series (typically 1:50-1:200)

  • Consider testing antibodies targeting different ERGIC2 epitopes

• Antigen retrieval enhancement:

  • For paraffin sections, optimize heat-mediated antigen retrieval with citrate buffer (pH 6.0)

  • For frozen sections, try detergent-based permeabilization optimization

• Signal amplification strategies:

  • Implement tyramide signal amplification (TSA)

  • Use biotin-streptavidin amplification systems

  • Consider secondary antibodies with brighter fluorophores

• Microscope settings optimization:

  • Increase exposure time (while monitoring photobleaching)

  • Adjust gain and offset settings

  • Use deconvolution to improve signal clarity

• Technical considerations:

  • Ensure samples remain hydrated throughout the protocol

  • Block with appropriate serum (typically 5-10% from secondary antibody host species)

  • Include 0.1-0.3% Triton X-100 in antibody diluent for better penetration

If signals remain inconsistent, validate ERGIC2 expression in your samples using alternative methods like RT-PCR before troubleshooting further.

What approaches help distinguish between specific and non-specific ERGIC2 antibody binding?

To distinguish specific from non-specific ERGIC2 antibody binding:

• Peptide competition assays:

  • Pre-incubate ERGIC2 antibody with increasing concentrations of immunizing peptide

  • Compare binding patterns with and without peptide competition

  • Specific signals should diminish proportionally to peptide concentration

• Multiple antibody validation:

  • Test multiple antibodies targeting different ERGIC2 epitopes

  • Compare binding patterns across antibodies

  • Consistent localization with different antibodies suggests specificity

• Genetic validation:

  • Use CRISPR/Cas9 to knock out or knockdown ERGIC2

  • Compare antibody staining in wild-type vs. modified cells

  • Specific signals should be absent or significantly reduced in knockout samples

• Cross-reactivity assessment:

  • Test antibody on samples known to lack ERGIC2 expression

  • Evaluate potential cross-reactivity with related proteins using recombinant protein panels

  • This is important given documented cases of antibody cross-reactivity invalidating research findings

• Signal correlation with expression level:

  • Compare antibody signal intensity with known ERGIC2 expression levels across tissues

  • Quantitative correlation between signal and expression suggests specificity

• Technical controls:

  • Include isotype controls (non-specific IgG from same host species)

  • Perform secondary-only controls to check for non-specific secondary antibody binding

  • Use blocking peptides specific to secondary antibody to reduce background

These approaches are critical given documented issues with antibody specificity that have impacted research validity, as highlighted in studies of antibody validation .

How should contradictory ERGIC2 localization data be interpreted?

When facing contradictory ERGIC2 localization data, apply this methodological framework:

• Antibody-dependent variations assessment:

  • Compare antibodies targeting different ERGIC2 epitopes

  • Document which region each antibody targets (N-terminal, middle region, C-terminal)

  • Different epitopes may be differentially accessible in certain cellular contexts

• Fixation-dependent effects analysis:

  • Compare results across fixation methods (aldehyde vs. alcohol-based)

  • Note that membrane proteins often show fixation-dependent localization patterns

  • Membrane contacts like ERGIC-ERES may be particularly sensitive to fixation artifacts

• Cell type and physiological state considerations:

  • ERGIC2 may form tissue-specific complexes with different localizations

  • Stress conditions can trigger ERGIC remodeling and redistribution

  • Document exact experimental conditions, cell types, and treatments

• Temporal dynamics evaluation:

  • ERGIC2 localization may change during cellular processes

  • Consider time-course experiments to capture dynamic localization patterns

  • The ERGIC is a highly dynamic compartment that responds to stress

• Resolution limitations acknowledgment:

  • Standard confocal microscopy may not resolve structures separated by <200 nm

  • ERGIC-ERES contacts occur at distances as close as 2-5 nm

  • Super-resolution approaches may be necessary for accurate localization

• Biochemical fractionation correlation:

  • Complement imaging with organelle fractionation studies

  • Compare subcellular distribution across methods

When reporting contradictory localization data, document all methodological details and discuss potential biological explanations for the observed differences, as the ERGIC is known to sub-compartmentalize for multifunctional needs .

How does ERGIC2 contribute to autophagosome formation pathways?

Recent research has revealed ERGIC2's crucial role in autophagosome formation:

• ERGIC-ERES contact formation: ERGIC2 helps establish membrane contacts between the ERGIC and ERES—a newly identified structural feature with distances as close as 2-5 nm . This proximity is significantly closer than conventional organelle contacts (10-30 nm).

• Transactivation mechanism: These close contacts enable a unique transactivation mechanism where ERES-localized SEC12 can physically reach across to the ERGIC membrane to trigger COPII vesicle formation . The SEC12 cytoplasmic domain (5.5 × 5 × 5.2 nm) can bridge this gap due to the unusually close contact.

• SEC12 translocation: Beyond transactivation, another mechanism involves the actual relocation of SEC12 from ERES to ERGIC as a means of generating ERGIC-COPII vesicles . This translocation occurs in response to cellular stress.

• Autophagosome precursor generation: The coordinated action of ERGIC and ERES through both these mechanisms (transactivation and translocation) enables the generation of autophagosome precursors .

• Stress response pathways: The ERGIC acts as a membrane platform that orchestrates autophagosome generation specifically in response to stress conditions , representing a specialized function distinct from its classical role in ER-Golgi trafficking.

These findings significantly expand our understanding of ERGIC2's functions beyond conventional secretory pathway roles, positioning it as a multifunctional protein involved in cellular stress responses.

What are the comparative advantages of different ERGIC2 detection methodologies?

Different ERGIC2 detection methodologies offer distinct advantages for specific research contexts:

For ERGIC-ERES contact studies, super-resolution immunofluorescence combined with electron microscopy has proven particularly valuable due to the extremely close (2-5 nm) contact distances . For tissue-specific interaction studies, co-immunoprecipitation from distinct tissues provides critical insights, as demonstrated in the ERGIC2-Otoferlin interaction studies .

How can ERGIC2 research inform our understanding of disease mechanisms?

ERGIC2 research offers several potential insights into disease mechanisms:

• Neurodegenerative diseases: The interaction between ERGIC2 and Otoferlin in brain tissue suggests potential roles in neuronal function. Given that disruptions in ER-Golgi trafficking are implicated in neurodegenerative conditions, ERGIC2 dysfunction might contribute to these pathologies.

• Autophagy-related disorders: ERGIC2's involvement in stress-induced autophagosome formation connects it to diseases with autophagy dysregulation, including:

  • Neurodegenerative conditions (Alzheimer's, Parkinson's)

  • Cancer (where autophagy plays context-dependent roles)

  • Metabolic disorders

• Viral pathogenesis: The ERGIC has been identified as a membrane station supporting coronavirus assembly . Understanding ERGIC2's function could provide insights into viral hijacking of cellular machinery and potential therapeutic targets.

• Hearing disorders: While direct ERGIC2-Otoferlin interaction was not detected in cochlea, both proteins are expressed there . Given Otoferlin's critical role in hearing, investigating whether ERGIC2 indirectly affects cochlear function could inform hearing disorder mechanisms.

• ER stress-related conditions: As part of the ER-Golgi system, ERGIC2 may influence cellular responses to ER stress, which is implicated in diabetes, inflammation, and various other pathologies.

Research methodologies should include comparative studies of ERGIC2 expression and localization in disease models, proteomic analysis of ERGIC2 complexes in pathological conditions, and functional studies examining how ERGIC2 perturbation affects disease-relevant cellular processes.

What emerging technologies might enhance ERGIC2 antibody applications?

Several emerging technologies promise to enhance ERGIC2 antibody applications:

• Super-resolution microscopy advancements:

  • Expansion microscopy combined with ERGIC2 immunofluorescence to physically enlarge specimens

  • MINFLUX offering nanometer precision for studying ERGIC-ERES contacts

  • Light-sheet microscopy for rapid 3D imaging of ERGIC2 distribution

• Live-cell antibody applications:

  • Cell-permeable nanobodies against ERGIC2 for live monitoring

  • Split-fluorescent protein complementation for studying dynamic interactions

  • CRISPR-based endogenous tagging combined with anti-tag antibodies

• Mass spectrometry immunohistochemistry:

  • Imaging mass cytometry using metal-conjugated ERGIC2 antibodies

  • Mass spectrometry imaging of immunolabeled tissues for multiplexed analysis

  • These approaches allow simultaneous detection of dozens of proteins on a single specimen

• Microfluidic antibody analysis:

  • Automated microfluidic immunostaining for high-throughput ERGIC2 detection

  • Single-cell antibody binding analysis for heterogeneity studies

  • Organ-on-chip models combining physiological environments with antibody-based detection

• Machine learning for antibody validation:

  • AI-assisted analysis of antibody specificity patterns

  • Automated detection of non-specific binding

  • This is particularly relevant given documented concerns about antibody validation

• Advanced proximity labeling:

  • TurboID or miniTurbo fusions with ERGIC2 for rapid biotin labeling of proximal proteins

  • Split-TurboID for detecting specific protein-protein interactions in vivo